Search

Your search keyword '"Guillerm, Gaelle"' showing total 3 results
Start Over Author "Guillerm, Gaelle" Topic allogeneic stem cell transplantation
3 results on '"Guillerm, Gaelle"'

1. Outcomes after allogeneic hematopoietic stem cell transplantation for adults with primary mediastinal B cell lymphoma: a SFGM-TC and LYSA study.

Author

Le Calvez, Baptiste, Tessoullin, Benoit, Renaud, Loïc, Botella-Garcia, Carmen, Srour, Micha, Le Gouill, Steven, Guillerm, Gaelle, Gressin, Rémy, Nguyen Quoc, Stéphanie, Furst, Sabine, Chauchet, Adrien, Sibon, David, Lewalle, Philippe, Poiré, Xavier, Maillard, Natacha, Villate, Alban, Loschi, Michael, Paillassa, Jérôme, Beguin, Yves, and Dulery, Rémy

Subjects
RESEARCH, HOMOGRAFTS, CONFIDENCE intervals, GRAFT versus host disease, B cell lymphoma, RETROSPECTIVE studies, DISEASE incidence, MEDIASTINAL tumors, TREATMENT effectiveness, DESCRIPTIVE statistics, HEMATOPOIETIC stem cell transplantation, PROGRESSION-free survival, PROPORTIONAL hazards models, ADULTS
Abstract

Background: Despite therapeutic progress, 10 to 30% of adult patients with primary mediastinal B cell lymphoma (PMBCL) are primary refractory or experience early relapse (R/R). Allogeneic stem cell transplantation (allo-HSCT) thus remains a potentially curative option in this setting. Material and Methods: In this multicenter retrospective study, the outcomes of 33 French and Belgian adult patients allo-transplanted for R/R PMBCL between January 1999 and December 2018, were examined. Results: At allo-HSCT time, patients had received a median of 3 treatment lines, 50% of them were in complete response, 40% in partial response and 10% had a progressive disease. Forty-two percent of the donors were siblings and 39% matched related. The median follow-up for alive patients was 78 months (3.5–157). Considering the whole cohort, 2-year overall survival (OS), progression free survival (PFS) and graft-versus-host disease-free/relapse-free survival (GRFS) were 48% (95%CI: 33–70), 47% (95%CI: 33–68) and 38.5% (95%CI: 25–60) respectively. Cumulative incidence of relapse and non-relapse mortality rates were respectively 34% (95%CI: 18–50) and 18% (95%CI: 7–34). Disease status at transplant was the only factor predicting survivals, patients with progressive disease showing significant lower 2-year PFS (HR: 6.12, 95%CI: 1.32–28.31, p = 0.02) and OS (HR: 7.04, 95%CI: 1.52–32.75, p = 0.013). A plateau was observed for OS and PFS after 4 years with 10 patients alive after this date, suggesting that almost one third of the patients effectively salvaged and undergoing allo-SCT could be cured. Conclusion: This study indicates that allo-HSCT is a valid therapeutic option for R/R PMBCL, providing durable remissions. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

2. Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS

Author

Chevallier, Patrice, Labopin, Marie, de La Tour, Régis Peffault, Lioure, Bruno, Bulabois, Claude-Eric, Huynh, Anne, Blaise, Didier, Turlure, Pascal, Daguindau, Etienne, Maillard, Natacha, Yakoub-Agha, Ibrahim, Guillerm, Gaelle, Delage, Jeremy, Contentin, Nathalie, Bay, Jacques-Olivier, Beckerich, Florence, Bourhis, Jean-Henri, Detrait, Marie, Vigouroux, Stéphane, Francois, Sylvie, Legrand, Faézeh, Guillaume, Thierry, Mohty, Mohamad, Tc, Sfgm, Centre hospitalier universitaire de Nantes (CHU Nantes), Pathologies biliaires, fibrose et cancer du foie, Centre de Recherche Saint-Antoine (UMRS893), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Pierre et Marie Curie - Paris 6 - UFR de Médecine Pierre et Marie Curie (UPMC), Université Pierre et Marie Curie - Paris 6 (UPMC), Service d'Hémato-oncologie [CHU Saint-Louis], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département d'Oncologie et Hématologie [Strasbourg], Les Hôpitaux Universitaires de Strasbourg (HUS), Département de cancérologie et d'hématologie, CHU Grenoble-Hôpital Michallon, Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Service d'Hématologie clinique et thérapie cellulaire [CHU Limoges], CHU Limoges, Service d'hématologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Lille Inflammation Research International Center - U 995 (LIRIC), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHRU Brest - Service d'Hématologie (CHU-Brest-Hemato), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Laboratoire d'hématologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), CHU Clermont-Ferrand, Service d'hématologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Département d'hématologie [Gustave Roussy], Institut Gustave Roussy (IGR), Hospices Civils de Lyon (HCL), CHU Bordeaux [Bordeaux], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Centre Hospitalier Universitaire de Nice (CHU Nice), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Institut Pasteur de Lille, and Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)

Subjects
Male, Oncology, Cancer Research, Transplantation Conditioning, reduced-toxicity conditioning regimen, 0302 clinical medicine, allogeneic stem cell transplantation, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, Clofarabine, Original Research, reduced‐toxicity conditioning regimen, Adenine Nucleotides, Incidence (epidemiology), Hematopoietic Stem Cell Transplantation, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 3. Good health, Fludarabine, Leukemia, Myeloid, Acute, Treatment Outcome, 030220 oncology & carcinogenesis, Female, Vidarabine, medicine.drug, Adult, medicine.medical_specialty, Allogeneic transplantation, [SDV.CAN]Life Sciences [q-bio]/Cancer, Lower risk, lcsh:RC254-282, Young Adult, 03 medical and health sciences, Internal medicine, medicine, Humans, Transplantation, Homologous, Radiology, Nuclear Medicine and imaging, Aged, Retrospective Studies, Acute myeloid leukemia, business.industry, fludarabine, Clinical Cancer Research, Surgery, myelodysplastic syndrome, Transplantation, Regimen, clofarabine, Myelodysplastic Syndromes, Arabinonucleosides, business, Busulfan, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Follow-Up Studies, 030215 immunology
Abstract

International audience; We have retrospectively compared survivals between acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) patients who received either a clofarabine/busulfan (CloB2A2) or a fludarabine/busulfan (FB2A2) RIC regimen for allogeneic stem cell transplantation. Between 2009 and 2014, 355 allotransplanted cases were identified from the SFGM-TC registry as having received either the FB2A2 (n = 316, 56% males, median age: 59.2 years, AML 78.5%, first complete remission [CR1] 72%, median follow-up: 20 months) or the CloB2A2 (n = 39, 62% males, median age: 60.8 years, AML 62%, CR1 69%, median follow-up: 22.4 months) RIC regimen. In multivariate analysis, FB2A2 was associated with significant lower overall survival (OS, HR: 2.14; 95%CI: 1.05-4.35, P = 0.04) and higher relapse incidence (RI, HR: 2.17; 95%CI: 1.02-4.61, P = 0.04) and a trend for lower leukemia-free survival (LFS, HR: 1.75; 95%CI: 0.94-3.26, P = 0.08). These results were confirmed using a propensity score-matching strategy. However, when considering AML and MDS patients separately, the benefit of the CLOB2A2 regimen was restricted to AML patients (2-year OS FB2A2: 38% [14.5-61.6] vs. CloB2A2: 79.2% [62.9-95.4], P = 0.01; 2-year LFS FB2A2: 38% [16-59.9] vs. CloB2A2: 70.8% [52.6-89], P = 0.03). The better survivals were due to the lower risk of relapse in this CloB2A2 AML subgroup (2-year RI FB2A2: 41.2% [19-62.4] vs. CloB2A2: 16.7% [5-34.2], P = 0.05). This retrospective comparison suggests that the CloB2A2 RIC regimen can likely provide longer survival than that awarded by a FB2A2 RIC regimen and may become a new standard of care RIC regimen for allotransplanted AML patients. A prospective phase 3 randomized study is warranted.

Published
2016

3. Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase.

Author

Mollard, Lise-Marie, Chauveau, Aurélie, Boyer-Perrard, Françoise, Douet-Guilbert, Nathalie, Houot, Roch, Quintin-Roué, Isabelle, Couturier, Marie-Anne, Dagorne, Anaig, Malou, Mohamed, Le Calloch, Ronan, Luycx, Odile, Thepot, Sylvain, Hunault, Mathilde, Guillerm, Gaelle, Berthou, Christian, Ugo, Valérie, Lippert, Éric, and Ianotto, Jean-Christophe

Subjects
MYELOPROLIFERATIVE neoplasms, LEUKEMIA, AZACITIDINE, CANCER chemotherapy, STEM cell transplantation
Abstract

Myeloproliferative neoplasms (MPN) are chronic disorders that can sometimes evolve into accelerated or leukemic phases. We retrospectively identified 122 patients with such blastic phases. The overall median survival was four months: 10.2 months for patients treated with intensive treatments compared to three months for best supportive care (p = .005). Azacytidine, intensive chemotherapies, or allogeneic stem cell transplantation gave the highest median survivals with 9, 10.2, and 19.4 months, respectively. Accelerated phases (AP) had a longer median survival compared to acute leukemia (4.8 months vs. 3.1 months; p = .02). In this retrospective and observational study, we observe that the longest survivals are seen in patients eligible for intensive treatments. Azacytidine shows interesting results in patients non-fit for intensive chemotherapy. Supportive care should probably be restricted to elderly patients and those with unfavorable karyotype. An early diagnosis of AP could also result in a better survival rate. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results